Post-Acute Care Outcomes of Oncology Patients Discharged to a SNF

Sarguni Singh, MD[1], **Megan Eguchi, MPH**[2], **Sung-Joon Min, PhD**[3], **Stacy Fischer, MD**[4]

[1.]Division of Hospital Medicine, University of Colorado Denver, Aurora, Colorado

[2.]University of Colorado Cancer Center, Aurora, Colorado

[3.]Division of Health Care Policy & Research, University of Colorado Denver, Aurora, Colorado

[4.]Division of General Internal Medicine, University of Colorado Denver, Aurora, Colorado

Abstract

Background: After discharge from an acute care hospitalization, cancer patients may choose to pursue rehabilitative care in a skilled nursing facility (SNF)

Objective: To examine receipt of anti-cancer therapy, death, readmission, and hospice use of cancer patients who discharge to a SNF compared to those who discharge home or home with home health services in the 6 months following an acute care hospitalization.

Patients and Methods: We conducted a population-based cohort study using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database of patients with stage II - IV colorectal, pancreatic, urinary bladder, or lung cancer who had an acute care hospitalization between 2010–2013. A total of 58,770 cases were identified and patient groups of interest were compared descriptively using means and standard deviations for continuous variables and frequencies and percentages for categorical variables. Logistic regression was used to compare patient groups, adjusting for covariates.

Results: Of patients discharging to SNF, 21%, 17%, and 2% went on to receive chemotherapy, radiation, and targeted chemotherapy, respectively, whereas the rates were 54%, 28%, and 6% for patients discharging to home. Fifty-six percent of patients discharging to SNF died within 6 months of their hospitalization compared to 36% discharging to home. Thirty-day readmission rates were 29% and 28% for patients discharging to SNF and home, respectively. Twelve percent of patients in hospice received less than 3 days of hospice care prior to their death regardless of their discharge location.

Conclusion: Patients with cancer who discharge to a SNF are significantly less likely to go on and receive oncologic treatment of any kind and have higher mortality compared to patients who discharge home after an acute care hospitalization.

Correspondence: Sarguni Singh, MD, Leprino Building, 4th floor, 12401 E. 17th Avenue, Mailstop F-782, Aurora, Colorado 80045, Phone: 720-848-4289, Fax: 720-848-4293, sarguni.singh@ucdenver.edu.

Discussion: Further research is needed to understand and address patient goals of care prior to SNF discharge.

Introduction

Studies have shown a significant correlation between functional status and survival for patients with cancer.[1,2,3] The functional decline associated with progressive cancer is prognostic for health events that severely limit mobility and also with acute care hospitalizations.[4] After discharge from an acute care hospitalization, patients may choose to pursue rehabilitative care in a skilled nursing facility (SNF). SNF care is considered a transitional period - a place where patients who are too weak to discharge home can go to receive skilled nursing care and rehabilitative therapies. Patients who discharge to a SNF are typically older, more medically complex, and have higher hospital readmission rates than patients who are strong enough to discharge home.[5,6,7]

The use of institutional post-acute care has increased from 21% in 2000 to 26% in 2015, resulting in Medicare spending more than $59 billion for these services in 2015.[8,9] SNF services are covered by Medicare Part A (hospital insurance) which provides payments to SNF's for a set period of time to care for patients after a qualifying hospital stay. Importantly, the SNF is the only setting that Medicare reimburses for 24-hour care after an acute care hospitalization for patients who are not eligible for long term acute care or inpatient rehabilitation.

There are two important limitations for patients with cancer who discharge to a SNF. First, patients with cancer rarely receive chemotherapy while admitted to a SNF because infusion chemotherapy is considered an outpatient procedure and covered by Medicare Part B whereas SNF's are covered by Medicare Part A. To provide chemotherapy, SNFs would have to absorb the cost of administration and treatment. Second, availability of palliative care (PC) consultation remains limited for patients in the SNF.[10]

We sought to understand clinical outcomes of patients with stage II - IV pancreatic, colorectal, lung, and bladder cancer who discharge to a SNF when compared to patients who discharge home or home with home services. These cancer types were selected because we anticipated that these patients would have high rates of hospital admission and re-admission and likely be candidates for SNF discharge, thus providing us with a robust cohort of patients for our analysis. We assessed health care utilization by examining rates of receipt of cancer directed therapy, 30-day readmission, death, and hospice use 6 months after an acute care hospitalization. We hypothesized that the majority of patients who are discharged to a SNF do not subsequently receive oncologic treatment, have higher mortality and readmission rates, and lower hospice use when compared to patients who discharge home or home with home healthcare.

Methods

Data Source

The data source was the Surveillance, Epidemiology and End Results (SEER)-Medicare database. The SEER program collects data from select cancer registries covering approximately 28% of the U.S. population; 93% of persons age 65 and older in the SEER files are matched to the Medicare enrollment file. Seventy-two to 76% of the Medicare population enrolled in Medicare Fee-for-Service (FFS) during the years of our study. For cases enrolled in Medicare FFS, the combined file provides detailed demographic and clinical information collected by cancer registries at the time of diagnosis, plus covered health care services received prior to diagnosis, during initial treatment, and over the course of follow-up for the duration of available claims. The database also includes a limited set of census tract and zip code-level socioeconomic variables.[11]

Sample Selection

We selected patients with colorectal, pancreatic, bladder, or lung cancer diagnosed from 2010 to 2013. We excluded records from patients with a subsequent primary tumor or other prior cancer diagnoses other than Stage 0 or Stage 1 breast or cervical cancer, or non-metastatic prostate cancer diagnosed in the three years prior to the tumor of interest (total sample size, N = 301,776, including 5,242 patients with one of the accepted prior tumors specified). Our analysis only included de novo cancers and did not include recurrent cancers as this information is not provided in the SEER-Medicare database. We further restricted to patients with American Joint Committee on Cancer, 7th Edition (AJCC) Stage Group II-IV tumors at diagnosis to obtain the patient sample with regional or advanced disease (N = 190,692).[12,13]

We identified the patient sample for which we have complete claims data by restricting to patients age 66 years and older at diagnosis (N = 150,679) and excluding patients diagnosed at autopsy as well as those with a missing diagnosis date (n = 127) or with negative survival time (n = 359). We included only patients who were continuously enrolled in Medicare FFS Parts A and B from 12 months prior to diagnosis through death or the end of the study follow-up, December 2014 (N = 91,568).

The study sample was further limited to patients with a paid claim for a short-term inpatient stay subsequent to diagnosis that did not end in death or discharge to hospice (N = 64,160). We assigned the first stay occurring in the month of diagnosis or later as the index inpatient stay. We required that the index stay occur by June 2014, with continuous enrollment in Medicare FFS Part A and Part B for at least 6 months after discharge or until death if before 6 months, to ensure adequate follow-up for all outcome measures (N = 63,697). Furthermore, removing discharge locations other than the 3 settings of interest (eg, inpatient residential facility, Medicare certified long term care hospital, transfer to another hospital) brought the total sample to 58,770 patients. Of these, 29% (n = 16,936) had a prior oncologic visit (established) and 71% percent (n = 41,834) had no prior oncologic visit (unestablished) (Figure 1). The Colorado Multiple Institutional Review Board and the Duke Institutional Review Board approved this study.

Comparator Groups

Analyses were conducted among 3 comparison groups with discharge locations of interest: SNF, home, and home with home health service (N = 58,770). We defined a confirmed discharge to a SNF as the presence of a SNF claim with an admission date equal to the index discharge date. Discharges to home and to home with home health care were identified using the patient discharge status code reported on the inpatient claim.

Outcomes

The primary outcome was receipt of anti-cancer therapy following an inpatient hospitalization in the 6 months after discharge. Current Procedural Terminology (CPT) codes, Healthcare Common Procedure Coding System (HCPCS) codes, International Classification of Diseases, 9th Revision (ICD-9) procedure and diagnosis codes, and National Drug Codes (NDC) were used to identify treatment received, including radiation, chemotherapy, and targeted therapy. We included targeted therapy drugs approved by the Food and Drug Administration (FDA) for the tumor sites of interest that had specific HCPCS codes initiated prior to the December 2014. The selected drugs included bevacizumab, cetuximab, everolimus, panitumumab, ramucirumab, and ziv-aflibercept. Claims in the 6 months after discharge were used to obtain additional outcome measures: 30-day readmission, hospice use, and death. Hospice use was measured using the number of covered days of care reported on hospice claims in the 6 months following index discharge.

Control Variables

We used SEER variables to obtain patient demographics and tumor characteristics at diagnosis. We used claims to identify characteristics of the index inpatient stay, prior health conditions, health care services received as well as to generate the Charlson Comorbidity Index and identify specific conditions of interest using Chronic Conditions Data Warehouse algorithms. We also used treatment and other health care services received after diagnosis and prior to index admission including visits with an oncology specialist, prior radiation, chemotherapy, and targeted therapy, as covariates in the analysis.[14]

Statistical Analysis

The 3 patient groups of interest were compared descriptively using means and standard deviations for continuous variables and frequencies and percentages for categorical variables. SEER-Medicare provides only the month of the cancer diagnosis but does not include date or setting in which the diagnosis was made. Patients with and without prior oncologist visits were considered separately in subsequent analyses to identify those patients with a known cancer diagnosis prior to index hospitalization from patients who were diagnosed with a new cancer at the time of index hospitalization. Subsequent cancer directed treatment, mortality, readmission, and hospice use were compared by discharge setting using chi-square tests. Logistic regression was used to compare patient groups, adjusting for covariates. Kaplan-Meier estimates were used to compare survival curves by patient group. For patients discharged to SNF, statistically significant predictors for the outcomes were identified using logistic regression and Cox proportional hazards regression. The regression

models were developed using a random 50% subsample and validated on the remaining 50% subsample. Statistical significance was defined as p<0.05.

Results

Patient Characteristics

Our study population consisted of 58,770 people with stage II – IV colorectal (31%), lung (51%, with 77% non-small cell lung cancer), pancreatic (12%), or bladder cancer (6%) (Table 1). A total of 71% of patients were given a new cancer diagnosis at the time of index hospitalization (unestablished patients) whereas 29% of patients had a known cancer diagnosis before index hospitalization (established patients). Mean (SD) length of stay (LOS) for the index hospitalization was 6.9 (±SD5.8) for all patients. LOS was 5.0 (±SD3.8) days for patients discharging to home, 8.1 (±5.8) days for those discharging to home with home healthcare, and 10.6(±SD7.6) days for those discharging to a SNF.

Patient Outcomes

Of SNF discharges, 21%, 17%, and 2% of SNF went on to receive chemotherapy, RT, and targeted chemotherapy, respectively, compared to 54%, 28%, and 6%, respectively, among home discharges. Furthermore, 56% of SNF discharges died within 6 months of their hospitalization compared to 36% of patients who discharged home (Figure 2a and 2b). Thirty-day readmission rates were 29% and 28% for SNF and home discharges, respectively and 12% of patients in hospice received less than 3 days of hospice care prior to their death regardless of their discharge location. Patients who had a major bowel surgery seemed more likely to require SNF care after hospitalization.

A total of 29% of unestablished cancer patients who discharged to a SNF went on to receive any cancer treatment (chemotherapy, RT, targeted chemotherapy) compared to 60% of patients discharged home (Table 2).

For patients with a known cancer diagnosis and receipt of prior treatment, 42% of those discharged to a SNF went on to receive any further cancer treatment compared with 74% of those discharged home. Table 3.

Predictors of SNF success for Established and Unestablished Cancer Patients

For unestablished patients, those with lung, pancreatic, and bladder cancer were more likely to go on to receive any further treatment compared to those with colorectal cancer. Unestablished patients with stage III cancer were more likely to receive future treatment compared with those with stage IV cancer patients. Both established and unestablished patients with stage II cancer were less likely to receive future oncologic treatment compared to those with stage IV cancer. Both established and unestablished patients with cognitive impairment were less likely to receive future treatment.

For all patients discharged to a SNF, stage II and III cancer were associated with a lower risk of death and longer time to death (measured in months), indicated by a lower hazard of death when compared to stage IV cancer. For established cancer patients, those who had

received chemotherapy before their index hospitalization were less likely to die compared with those who had received no treatment before index admission (Table 4).

Discussion

This study describes post-acute care outcomes of patients with stage II – IV colorectal, lung, pancreatic, and bladder cancer discharged to a SNF after an acute care hospitalization. Data show that these patients are significantly less likely to go on and receive cancer treatment of any kind and are more likely to die within 6 months of discharge compared with patients discharged home. Only approximately one-fifth of patients discharged to a SNF received subsequent chemotherapy compared with slightly more than half of patients discharged home. This analysis also shows how ill this cancer population is - 42% of *all* patients who had an acute care hospitalization discharged to home, home with health care, and SNF had died within 6 months of discharge.

Although these findings are not unexpected, the magnitude of the difference in outcomes of patients who discharge to a SNF compared to those who discharge home is striking. This analysis of SEER Medicare data confirms previous research of SNF populations in general. Patients who discharge to a SNF are more frail, older, and have more comorbidities than those who discharge home. Thus, poorer outcomes in the SNF population of this study are not unexpected but rather most congruent with their projected outcomes based on their clinical morbidities. Although we attempted to adjust for patient-level differences, including hospital characteristics, the cohorts are inherently different, and the discharge location essentially serves as a surrogate for functional status. The intent of this study was to understand the impact of discharge location, as a surrogate for function, on subsequent rates of cancer directed treatment. The American Society of Clinical Oncology recommends against the use of chemotherapy in patients with solid tumors who have not benefited from prior treatment and who have an Eastern Cooperative Oncology Group (ECOG)[15] performance status (PS) score of 3 or more.[16] These findings suggest that if the intent of sending this patient population to a SNF is to recover functional status and receive cancer directed therapy, most patients will not realize this goal.

Discharging patients with cancer who have a poor prognosis to a SNF setting hinders the ability of patients to express their goals of care and participate in end of life planning due to limited access of palliative care in SNFs. Previous studies have shown that oncologists struggle with communicating prognosis and with saying "no" to continued chemotherapy treatment in patients with end stage cancer.[17,18] This struggle likely contributes to the poor prognostic understanding and unrealistic expectations patients experience at the end of their life. The proportion of patients using short-term hospice services (3 days or less) decreased from 9.8% to 7.7%. Our study revealed that 13.6% and 11.9% of patients who discharged to SNF or home, respectively, had a hospice LOS < 3 days.[19] These numbers are higher than national averages for both discharge locations (SNF and home). It is possible that the standard Medicare requirement to select either hospice or SNF care may lead to lower hospice enrollment. The Medicare Care Choices Model, allowing for concurrent hospice and cancer directed treatment, might increase hospice utilization in this population.[20]

This study reveals differences between patients with an established cancer diagnosis compared to those who were newly diagnosed with cancer. Patients with unestablished cancer were less likely to receive future oncologic treatment at all discharge locations compared with established cancer patients who had received prior oncologic treatment of any kind. We posit the functional decline that unestablished cancer patients experience is primarily driven by the malignancy itself while patients with established cancer and exposure to cancer directed therapy might be experiencing functional decline as a result of their treatment or a complication of treatment and thus might be more likely to regain functional strength to receive future cancer directed therapy after a SNF stay.

Results of this study should prompt consideration of the financial implications of discharging patients with cancer with functional decline to a SNF. Although readmissions were not statistically different between the discharge locations, 29% of patients were readmitted within 6 months of their acute care hospitalization. High hospital readmission rates from the post-acute care setting have become exceedingly problematic for hospitals and SNF's, because they now receive financial penalties for these readmissions and lower quality metrics. This is largely driven by the Medicare Hospital Readmission Reduction Program and the increasing prevalence of bundled payments and shared-savings programs since the passage of the Patient Protection and Affordable Care Act.[21,22] Feder, et al. studied hospital and SNF clinicians' perceptions of goals of care discussions for patients discharged to a SNF and found that discordant goals of care among patients, family members, and clinicians were perceived to contribute to poor patient outcomes at SNF and to increased hospital readmissions.[23]

Limitations

Our study has several limitations. The SEER-Medicare data set is a secondary claims database that does not provide a measure of functional status or social support, which are both factors that might influence disposition after acute care hospitalization and the outcomes we measured. We do not know the goals of patients in discharging to a SNF. Regardless, CMS has set up a reimbursement infrastructure with the view that SNF's are to serve a rehabilitative function. Our analysis of SEER-Medicare data from 2010–2013 is immediately prior to the increase in the use of immunotherapy – a treatment which might not have the same performance status requirements as traditional cytotoxic chemotherapy. Preliminary research has shown that older patients with an ECOG PS of 2 or higher had poor outcomes despite receipt of immunotherapy and that overall survival was primarily driven by a patient's ECOG PS.[24] Further research is needed to understand the relationship between immunotherapy and functional outcomes as these patient populations were under-represented in clinical trials involving those with immunotherapies.[25] We note that patients with earlier stage disease might have received surgery as their primary treatment modality and might not be candidates for adjuvant treatment. Evaluating post-acute care outcomes of cancer patients undergoing primary surgical treatment of their malignancy is an important line of inquiry but beyond the scope of this paper. Lastly, future receipt of outpatient oral cancer directed therapy was not captured in this study as oral medications are covered by Medicare Part D and these claims were not analyzed.

Conclusion

Our study shows that the majority of patients with stage II - IV colorectal, lung, bladder, and pancreatic cancer who discharge to a SNF are less likely to receive cancer directed treatment and more likely to die compared to those who are functionally able to discharge home. Next steps include better understanding patients' goals of care when discharging to a SNF and developing and implementing targeted interventions that improve Palliative Care delivery models to patients in the SNF setting.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Funding

References

1. Verweij NM, Schiphorst AH, Pronk A, et al.Physical performance measures for predicting outcome in cancer patients: a systematic review. Acta Oncol. 201612;55(12)1386–1391. [PubMed: 27718777]

2. Studenski S, Perera S, Patel K. Gait speed and survival in older adults. JAMA2011; 305:50–8. [PubMed: 21205966]

3. Stanaway FF, Gnjidic D, Blyth FM, et al.How fast does the Grim Reaper walk? Receiver operating characteristics curve analysis in healthy men aged 70 and over. BMJ. 2011;343:d7679. [PubMed: 22174324]

4. Cesari M, Kritchevsky SB, Newman AB, et al.Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging, and Body Composition Study. J AM Geriatr Soc. 2009;57:251–9. [PubMed: 19207142]

5. Burke RE, Juarez-Colunga E, Levy C, et al.Rise of post-acute care facilities as a discharge destination of US hospitalizations. JAMA Intern Med. 20152;175(2):295–296. [PubMed: 25437642]

6. Mor V, Intrator O, Feng Z, et al.The revolving door of rehospitalization from skilled nursing facilities. Health Aff Proj Hope. 20102;29(1):57–64.

7. Neuman MD, Wirtalla C, Werner RM. Association between skilled nursing facility quality indicators and hospital readmissions. JAMA. 20141015;312(15:1542–1551. [PubMed: 25321909]

8. Werner R, Konetzka T. Trends in Post-Acute Care Use Among Medicare Beneficiaries 2000 to 2015. JAMA. 2018;319(15):1616–1617. [PubMed: 29677292]

9. Redberg RThe Role of Post-Acute Care in Variation in the Medicare Program. JAMA Intern Med. 2015;175(6):1058.

10. Lester PE, Stefanacci RG, Feuerman M. Prevalence and description of palliative care in US nursing homes: a descriptive study. Am J Hosp Palliat Care. 2016;33:171–177. [PubMed: 25395553]

11. Surveillance, Epidemiology, and End Results (SEER) Program; National Cancer Institute. Overview of the SEER Program. https://seer.cancer.gov/about/overview.html

12. National Cancer Institute, Division of Cancer Control and Population Sciences. SEER-Medicare: Medicare Enrollment & Claims Data. https://healthcaredelivery.cancer.gov/seermedicare/medicare/

13. National Cancer Institute, Division of Cancer Control and Population Sciences. SEER-Medicare: How the SEER & Medicare Data are Linked. https://healthcaredelivery.cancer.gov/seermedicare/overview/linked.html

14. Center for Medicare and Medicaid Services. Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories

15. Eastern Cooperative Oncology Group. ECOG performance status. http://ecog-acrin.org/resources/ecog-performance-status.

16. Schnipper LE, Smith TJ, Raghavan D, et al.American Society of Clinical Oncology identifies give key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):17175–1724.

17. Berenson RA, Paulus RA, Kalman NS. Medicare's readmissions-reduction program—a positive alternative. N Engl J Med. 2012412;366(15):1363–1366

18. Cutler DM, Ghosh K. The potential for cost savings through bundled episode payments. N Engl J Med. 2012322;366(12):1075–1077. [PubMed: 22435368]

19. Teno JM, Gozalo P, Trivedi AN, et al.Site of death, place of care and health care transitions among US Medicare beneficiaries, 2000 – 2015. JAMA2018;320:264–271. [PubMed: 29946682]

20. US Centers for Medicare & Medicaid Services. Medicare Care Choices Model enables concurrent palliative and curative care. J Pain Palliat Care Pharmacother2015;29:401–403. [PubMed: 26654414]

21. Berenson RA, Paulus RA, Kalman NS. Medicare's readmissions-reduction program – a positive alternative. N Engl J Med2012;366:1364–1366. [PubMed: 22455754]

22. Cutler DM, Ghosh K. The potential for cost savings through bundled episode payments. N Engl J Med2012;366:1075–1077. [PubMed: 22435368]

23. Feder SL, Britton MC, Chaudhry SI. "The Need to Have an Understanding of Why They're Coming Here and What Outcomes Might Be." Clinician Perspectives on Goals of Care for Patients Discharging from Hospitals to Skilled Nursing Facilities. J Pain Symptom Manage. 20183;55(3):930–937. [PubMed: 29097273]

24. Muchnik E, Loh KP, Strawderman M, et al.Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer. J AM Geriatr Soc2019;67:905–912. [PubMed: 30698276]

25. Kanesvaran R, Cordoba R, Maggiore R. Immunotherapy in Older Adults with Advanced Cancers: Implications for Clinical-Decision Making and Future Research. Am Soc Clin Oncol Educ Book. 2018523;(38):400–414. [PubMed: 30231397]

Figure 1.
SEER-Medicare analysis sample derivation

Figure 2a.
Kaplan Meier Survival Curve – Unestablished Cancer Patients

Figure 2b.
Kaplan Meier Survival Curve – Established Cancer Patients

Table 1.

Patient and Index Hospitalization Characteristics by Discharge Setting (n (%) or mean ± SD unless otherwise specified) – SEER-Medicare 2010–2013

Characteristic		All	Home	Home Health	SNF
Total patients - N (% of the whole study sample 58770)		58770 (100%)	33057 (56%)	13592 (23%)	12121 (21%)
Male (vs. Female)		29747 (50.6%)	17770 (53.4%)	6716 (49.4%)	5261 (43.4%)
Age (years)	Index Admission	77.6 ± 7.1	76.2 ± 6.6	77.9 ± 7.0	81.0 ± 7.2
Months between Diagnosis and Index Admission		2.5 ± 3.8	2.6 ± 3.9	2.6 ± 3.7	2.4 ± 3.7
Race					
	White NH	47668 (81.2%)	26733 (81.0%)	10826 (79.7%)	10109 (83.4%)
	Black NH	4974 (8.5%)	2697 (8.2%)	1331 (9.8%)	946 (7.8%)
	Hispanic	3070 (5.2%)	1791 (5.4%)	746 (5.5%)	533 (4.4%)
Asian or Pacific Islander/American Indian/Alaska Native NH		3002 (5.1%)	1803 (5.5%)	678 (5.0%)	521 (4.3%)
Married or Partnered (vs. Non-married)		29366 (50.0%)	18547 (56.1%)	6726 (49.5%)	4093 (33.8%)
Census Tract Socioeconomic Status (SES)					
	Median Income ($)	61513.9 ± 25634.1	60509.0 ± 25300.2	62071.9 ± 26359.9	63635.6 ± 25566.1
% of Residents below Poverty		14.0 ± 9.3	14.3 ± 9.3	14.1 ± 9.3	13.2 ± 9.1
% of Non-High School Grads		14.4 ± 9.8	14.6 ± 9.9	14.6 ± 10.1	13.7 ± 9.5
Charlson Comorbidity Index					
	0	19452 (33.1%)	11848 (35.8%)	4210 (30.1%)	3394 (28.0%)
	1	16946 (28.8%)	9879 (29.9%)	3933 (28.9%)	3134 (25.9%)
	2	9845 (16.8%)	5288 (16.0%)	2333 (17.2%)	2224 (18.4%)
	3 or more	12527 (21.3%)	6042 (18.3%)	3116 (22.9%)	3369 (27.8%)
Year of Diagnosis					
	2010	15334 (26.1%)	8601 (26.0%)	3574 (26.3%)	3159 (26.1%)
	2011	14812 (25.2%)	8431 (25.5%)	3358 (24.7%)	3023 (24.9%)
	2012	14714 (25.0%)	8270 (25.0%)	3372 (24.8%)	3072 (25.3%)
	2013	13910 (23.7%)	7755 (23.5%)	3288 (24.2%)	2867 (23.7%)
Cancer Type & Stage					
	Colorectal	18472 (31.4%)	9666 (29.2%)	4239 (31.2%)	4567 (37.7%)

Characteristic		All	Home	Home Health	SNF
	Stage II	7498 (40.6%)	3941 (40.8%)	1675 (39.5%)	1882 (41.2%)
	Stage III	6528 (35.3%)	3545 (36.7%)	1474 (34.8%)	1509 (33.0%)
	Stage IV	4446 (24.1%)	2180 (22.6%)	1090 (25.7%)	1176 (25.8%)
Lung		29792 (50.7%)	17218 (52.1%)	6823 (50.2%)	5751 (47.5%)
	Stage II	3551 (11.9%)	2139 (12.4%)	834 (12.2%)	578 (10.1%)
	Stage III	7634 (25.6%)	4688 (27.2%)	1655 (24.3%)	1291 (22.5%)
	Stage IV	18607 (62.5%)	10391 (60.4%)	4334 (63.5%)	3882 (67.5%)
Pancreas		6897 (11.7%)	4303 (13.0%)	1531 (11.3%)	1063 (8.8%)
	Stage II	2521 (36.6%)	1507 (35.0%)	613 (40.0%)	401 (37.7%)
	Stage III	692 (10.0%)	469 (10.9%)	135 (8.8%)	88 (8.3%)
	Stage IV	3684 (53.4%)	2327 (54.1%)	783 (51.1%)	574 (54.0%)
Bladder		3609 (6.1%)	1870 (5.7%)	999 (7.4%)	740 (6.1%)
	Stage II	2000 (55.4%)	1037 (55.5%)	531 (53.2%)	432 (58.4%)
	Stage III	639 (17.7%)	335 (17.9%)	196 (19.6%)	108 (14.6%)
	Stage IV	970 (26.9%)	498 (26.6%)	272 (27.2%)	200 (27.0%)
Health Care Utilization prior to Index Admission					
One or More SNF Stays		5181 (8.8%)	1279 (3.9%)	800 (5.9%)	3102 (25.6%)
Visit with Oncologist		16936 (28.8%)	9763 (29.5%)	4351 (32.0%)	2822 (23.3%)
Chemotherapy		9584 (16.3%)	5588 (16.9%)	2529 (18.6%)	1467 (12.1%)
Radiation		6641 (11.3%)	3652 (11.1%)	1803 (13.3%)	11.86 (9.8%)
Targeted Chemotherapy		1131 (1.9%)	669 (2.0%)	281 (2.1%)	181 (1.5%)
Index Hospital Characteristics					
Location					
Urban (vs. Rural)		53137 (91.2%)	29746 (90.1%)	12401 (92.1%)	10990 (90.7%)
Type					
Teaching (vs. Non-teaching)		32107 (55.1%)	17847 (54.5%)	7767 (57.7%)	6493 (53.6%)
Index Stay DRG (top 10 listed, *surgical)					

Characteristic	All	Home	Home Health	SNF
*330 MAJOR SMALL AND LARGE BOWEL PROCEDURES WITH CC	7117 (12.2%)	3704 (11.3%)	1768 (13.1%)	1645 (13.6%)
181 RESPIRATORY NEOPLASMS WITH CC	3441 (5.9%)	2117 (6.4%)	730 (5.4%)	594 (4.9%)
180 RESPIRATORY NEOPLASMS WITH MCC	3196 (5.5%)	1563 (4.7%)	840 (6.2%)	793 (6.6%)
*329 MAJOR SMALL AND LARGE BOWEL PROCEDURES WITH MCC	2767 (4.7%)	615 (1.9%)	762 (5.6%)	1390 (11.5%)
*331 MAJOR SMALL AND LARGE BOWEL PROCEDURES WITHOUT CC/MCC	2477 (4.2%)	1813 (5.5%)	428 (3.2%)	236 (2.0%)
*164 MAJOR CHEST PROCEDURES WITH CC	2276 (3.9%)	1399 (4.3%)	623 (4.6%)	254 (2.1%)
*167 OTHER RESPIRATORY SYSTEM O.R. PROCEDURES WITH CC	1437 (2.5%)	895 (2.7%)	350 (2.6%)	192 (1.6%)
*166 OTHER RESPIRATORY SYSTEM O.R. PROCEDURES WITH MCC	1315 (2.2%)	618 (1.9%)	367 (2.7%)	330 (2.7%)
435 MALIGNANCY OF HEPATOBILIARY SYSTEM OR PANCREAS WITH MCC	1276 (2.2%)	798 (2.4%)	283 (2.1%)	195 (1.6%)
375 DIGESTIVE MALIGNANCY WITH CC	1258 (2.1%)	898 (2.7%)	180 (1.3%)	180 (1.5%)

Data were rarely missing (<1%, except SES variables ~4%).

P-values are not shown because all comparisons were highly significant due to the large sample size.

CC – complication or comorbidity; MCC – major complication or comorbidity

Table 2.

Outcomes at 6 Months – Unestablished Cancer Patients

		Home	Homecare	SNF	p-value	Adjusted ± OR (95% CI) vs Home			
						Homecare	Adjusted p-value	SNF	Adjusted p-value
	N=41834	N=23294	N=9241	N=9299					
Any Treatment	N=4116 *	13646 (59.5%)	4530 (50.0%)	2649 (28.8%)	<0.001	0.78 (0.73–0.82)	<0.001	0.40 (0.37–0.42)	<0.001
Any Chemotherapy Infusion	N=4121 *	11677 (50.9%)	3592 (39.6%)	1675 (18.2%)	<0.001	0.74 (0.70–0.79)	<0.001	0.32 (0.30–0.34)	<0.001
Radiation	N=4176 *	6279 (27%)	2251 (24.4%)	1490 (16%)	<0.001	0.94 (0.88–1.00)	0.04	0.66 (0.62–0.71)	<0.001
Targeted Chemotherapy	N=4175 *	1265 (5.4%)	448 (4.9%)	194 (2.0%)	<0.001	0.89 (0.78–1.004)	0.06	0.41 (0.34–0.48)	<0.001
Death 6 months following admission		8178 (35.1%)	3966 (42.9%)	5141 (55.3%)	<0.001	1.36 (1.28–1.45)	<0.001	2.49 (2.31–2.67)	<0.001
Hospice use 6 months following admission	N=1728 **	5159 (63.1%)	2619 (66.0%)	2706 (52.6%)	<0.001	1.14 (1.05–1.24)	0.003	0.64 (0.59–0.70)	<0.001
Hospice LOS < 3 days	N=1048 ***	616 (11.9%)	307 (11.7%)	368 (13.6%)	0.06	1.01 (0.86–1.17)	0.95	1.22 (1.05–1.42)	0.01
30-day Readmission		6693 (28.7%)	2699 (29.2%)	2688 (28.9%)	0.69	1.00 (0.95–1.06)	0.98	1.03 (0.97–1.09)	0.37

*
Excludes few cases with data error where prior cancer treatment is indicated

**
Number of patients who died

***
Number of patients who received hospice before death

±
prior treatment (prior chemotherapy, prior radiation, and prior targeted chemotherapy; or prior any therapy for any treatment outcome), discharge year, cancer type and stage, grade, age at index admission, months between diagnosis and index admission, male, white NH, urban, index hospital region and characteristics, prior hypertension, prior diabetes, prior COPD, prior heart disease, prior stroke, prior cognitive disorder, index admission LOS, Charlson comorbidity index categories, per capita income, median income, percent of non-high school grads, percent of residents below poverty, married or partnered, prior depressive disorders, prior alcohol use disorder, prior drug use, prior tobacco use.

Table 3.

Outcomes at 6 Months – Established Cancer Patients

		Home	Homecare	SNF	p-value	Adjusted ± OR (95% CI) vs Home			
		N=9763	N=4351	N=2822		Homecare	Adjusted p-value	SNF	Adjusted p-value
	N=16936								
Any Treatment		4483 (73.5%)	1772 (63.3%)	736 (42.1%)	<0.001	0.72 (0.67–0.79)	<0.001	0.39 (0.35–0.43)	<0.001
Prior Receipt	N=10648 *								
Chemotherapy		3615 (68.9%)	1358 (57.7%)	447 (32.9%)	<0.001	0.71 (0.66–0.77)	<0.001	0.34 (0.30–0.38)	<0.001
Prior Receipt	N=8963 *								
Radiation		1496 (41.5%)	553 (30.9%)	299 (25.4%)	<0.001	0.83 (0.76–0.91)	<0.001	0.66 (0.59–0.75)	<0.001
Prior Receipt	N=6570 *								
Targeted Chemotherapy		287 (45.6%)	93 (35.6%)	36 (22.1%)	<0.001	0.71 (0.58–0.85)	<0.001	0.44 (0.33–0.57)	<0.001
Prior Receipt	N=1054 *								
Death 6 months following admission	N=7247 **	3746 (38.4%)	1902 (43.7%)	1599 (56.7%)	<0.001	1.46 (1.34–1.59)	<0.001	2.51 (2.27–2.78)	<0.001
Hospice use 6 months following admission	N=4622 ***	2484 (66.3%)	1231 (64.7%)	907 (56.7%)	<0.001	0.93 (0.82–1.05)	0.23	0.68 (0.59–0.78)	<0.001
Hospice LOS < 3		255 (10.3%)	123 (10.0%)	122 (13.5%)	0.02	0.94 (0.74–1.18)	0.58	1.28 (0.999–1.63)	0.0501
30-day Readmission		2403 (24.6%)	1245 (28.6%)	823 (29.2%)	<0.001	1.20 (1.10–1.31)	<0.001	1.20 (1.07–1.34)	0.001

*
Number of patients who received cancer treatment before index hospitalization

**
Number of patients who died

***
Number of patients who received hospice before death

±
prior treatment (prior chemotherapy, prior radiation, and prior targeted chemotherapy; or prior any therapy for any treatment outcome), discharge year, cancer type and stage, grade, age at index admission, months between diagnosis and index admission, male, white NH, urban, index hospital region and characteristics, prior hypertension, prior diabetes, prior COPD, prior heart disease, prior stroke, prior cognitive disorder, index admission LOS, Charlson comorbidity index categories, per capita income, median income, percent of non-high school grads, percent of residents below poverty, married or partnered, prior depressive disorders, prior alcohol use disorder, prior drug use, prior tobacco use.

Table 4.

Predictors for SNF Success in Outcomes at 6 Months - Established Cancer Patients (OR (95% CI) unless otherwise specified)

Variable		Any Treatment	Death	Hospice	Hospice LOS < 3	30-day Readmission	Months to Death HR [*] (95% CI)
		N=1411	N=1397	N=805	N=460	N=1397	N=1397
		c=0.64	c=0.75	c=0.66	c=0.57	c=0.62	
Male (vs. Female)			1.66 (1.30–2.11)				1.22 (1.08–1.37)
Age (years) at Index Admission		0.96 (0.94–0.98)					1.015 (1.01–1.024)
Months between Diagnosis and Index Admission		0.95 (0.93–0.97)					
White NH (vs. Other)				1.54 (0.99–2.38)			
Married or Partnered (vs. Non-married)							
Urban				1.85 (1.15–2.98)			1.27 (1.001–1.61)
SES							
Per Capita Income ($1000)							
Median Income ($1000)							
% of Residents below Poverty							
% of Non-High School Grads							
Charlson Comorbidity Index Categories						1.16 (1.04–1.29)	
Cancer Type (vs. Colorectal)							
	Lung		2.83 (2.05–3.92)			1.32 (0.97–1.79)	1.85 (1.53–2.22)
	Pancreas		3.55 (2.23–5.65)			1.07 (0.68–1.69)	2.36 (1.86–3.00)
	Bladder		1.66 (0.93–2.97)			2.07 (1.26–3.41)	1.2 (0.87–1.70)
Cancer Stage (vs. Stage IV)							
	Stage II	0.60 (0.45–0.80)	0.31 (0.22–0.42)			0.74 (0.54–1.02)	0.52 (0.44–0.61)
	Stage III	0.94 (0.73–1.22)	0.33 (0.24–0.44)			0.71 (0.53–0.94)	0.55 (0.47–0.63)
Grade [**] (vs. 9)							
	1		0.33 (0.17–0.64)				0.54 (0.38–0.76)
	2		0.55 (0.39–0.77)				0.71 (0.59–0.85)
	3		0.74 (0.54–1.002)				0.87 (0.75–1.01)
	4		1.28 (0.71–2.31)				1.02 (0.75–1.40)

Variable	Any Treatment	Death	Hospice	Hospice LOS < 3	30-day Readmission	Months to Death HR* (95% CI)
Prior to Index Admission						
One or More SNF Stays						
Any Therapy						
Chemotherapy		0.67 (0.52–0.87)				
Radiation		1.68 (1.28–2.20)				1.18 (1.04–1.34)
Targeted Chemotherapy			2.34 (1.18–4.62)			
HTN		0.74 (0.55–0.99)				0.82 (0.72–0.94)
Diabetes						
COPD						1.16 (1.02–1.32)
Heart						
Stroke			0.47 (0.25–0.89)			
Cognitive	0.44 (0.27–0.69)	1.84 (1.17–2.88)				
Alcohol					2.39 (1.23–4.63)	
Depression			1.60 (1.08–2.38)			
Index Hospital						
Region (vs. West)						
Northeast			1.98 (1.40–2.81)			
Midwest			3.90 (2.21–6.88)			
South			1.86 (1.20–2.88)			
Location: Urban (vs. Rural)					2.01 (1.22–3.33)	0.69 (0.53–0.91)
Type: Teaching (vs. Non-teaching)		0.76 (0.60–0.96)				0.85 (0.76–0.96)
LOS			0.96 (0.94–0.99)	0.92 (0.86–0.99)	1.03 (1.01–1.05)	
Discharge Year						

*
Hazard Ratio

**
Grade I: well differentiated; differentiated, NOS

Grade 2: moderately differentiated; moderately differentiated; intermediate differentiation

Grade 3: poorly differentiated; differentiated

Grade 4: undifferentiated; anaplastic

Grade 9: cell type not determined, not stated or not applicable